This application is based upon and claims the benefit of priority from prior Japanese patent application No. 2014-011350, filed on Jan. 24, 2014, the entire contents of which are incorporated herein by reference.
The presently disclosed subject matter relates to a monitoring apparatus for heart failure.
Recently, heart failure becomes one of diseases which frequently occur. In order to prevent heart failure from occurring, for example, it is contemplated to previously determine the possibility of onset of heart failure. JP-T-2012-523262 discloses a method for monitoring pulmonary congestion in a subject based on parameters of the breathing of the subject, in order to previously detect the possibility of onset of heart failure.
In the method for monitoring pulmonary congestion in a subject, which is disclosed in JP-T-2012-523262, however, the possibility of onset of heart failure can be detected, but the specific cause of the onset cannot be determined.
The presently disclosed subject matter may provide a monitoring apparatus in which the specific cause of onset of heart failure can be determined.
The monitoring apparatus may comprise a condition determining section which is configured to determine a condition of one of a heart, lungs, and blood vessels based on: a concentration of carbon dioxide in an expired gas which is measured by using a first sensor; and an oxygen transport parameter or a metabolic parameter which is measured by using a second sensor.
The first sensor may measure an expired end-tidal carbon dioxide concentration which is a concentration of the carbon dioxide in the expired gas during an end-tidal phase of expiration.
The oxygen transport parameter or the metabolic parameter may include one of an SpO2, blood gas information, a blood pressure, a cardiac output, a cardiac index, a pulsation rate, a body temperature, a pulse rate, and a heart rate.
The cardiac output may be non-invasively measured.
The second sensor may be configured by a pulse wave sensor for measuring a pulse wave, and an electrocardiogram sensor for measuring an electrocardiogram, and non-invasively measure the cardiac output based on the pulse wave and the electrocardiogram.
The condition of one of the heart, the lungs, and the blood vessels which is determined by the condition determining section may be one of heart failure, a ventilation condition, a condition of pulmonary congestion or pulmonary hypertension, and a condition of acute pulmonary congestion or pulmonary hypertension.
The monitoring apparatus may further comprise: a displaying section which is configured to display in a form of a graph the condition of one of the heart, the lungs, and the blood vessels, the condition being classified based on the concentration of the carbon dioxide and the oxygen transport parameter or the metabolic parameter.
A determination reference value for determining the condition of one of the heart, the lungs, and the blood vessels may be indicated in the graph displayed on the displaying section.
Hereinafter, embodiments of the monitoring apparatus of the presently disclosed subject matter will be described in detail with reference to the drawings.
As shown in
The capnometer 2 is a sensor which measures the concentration (%) or partial pressure (mmHg) of carbon dioxide contained in the inspired and expired gases of the subject. When a CO2 sensor or a sampling tube is attached to the nose or mouth of the subject, the capnometer 2 can non-invasively measure the concentration or the like of carbon dioxide contained in the inspired and expired gases. In the embodiment, the capnometer 2 is configured so as to measure the expired end-tidal carbon dioxide partial pressure (ETCO2) exhibiting the concentration of carbon dioxide during the end-tidal phase of expiration in which the concentration in the expired gas is highest. The capnometer 2 is connected to the processing device 5 so that the ETCO2 measured by the capnometer 2 is sent to the processing device 5.
The pulse oximeter 3 is a sensor which measures the pulse rate, the arterial blood oxygen saturation (SpO2), and the like. When a probe is attached to the fingertip or ear of the subject, the pulse oximeter 3 can non-invasively measure the pulse rate and the SpO2. In the embodiment, the pulse oximeter 3 is configured so as to measure the SpO2 which is the oxygen saturation of the arterial blood. The pulse oximeter 3 is connected to the processing device 5 so that the SpO2 measured by the pulse oximeter 3 is sent to the processing device 5. The second sensor is not limited to the pulse oximeter, and any sensor may be used as far as the sensor can measure an oxygen transport parameter or a metabolic parameter. The oxygen transport parameter or the metabolic parameter may be the SpO2, blood gas information, the blood pressure, the cardiac output, the cardiac index, the pulsation rate, the body temperature, the pulse rate, the heart rate, or the like. As the second sensor, for example, a pulse wave sensor for measuring the pulse wave, and an electrocardiogram sensor for measuring an electrocardiogram are useful. Based on the pulse wave and electrocardiogram which are measured by a pulse wave sensor and an electrocardiogram sensor, the cardiac output can be non-invasively measured.
The processing device 5 includes a condition determining section 6, a memory section 7, and a displaying section 8.
The condition determining section 6 determines the conditions of the heart, the lungs, and blood vessels of the subject based on the ETCO2 measured by using the capnometer 2, and the SpO2 measured by using the pulse oximeter 3. On the basis of the determined condition of the respiratory system, the condition determining section 6 classifies decreases which cause heart failure, and determines the condition (severity). As described above, the condition determining section 6 can determine the condition of one of the heart, the lungs, and blood vessels based on the measurement result of the ETCO2 and the oxygen transport parameter or the metabolic parameter. The conditions of the heart, the lungs, and blood vessels include heart failure, the ventilation condition, the condition of pulmonary congestion or pulmonary hypertension, and the condition of acute pulmonary congestion or pulmonary hypertension, or the like.
The memory section 7 stores biological information including the ETCO2 and SpO2 which are measured by the capnometer 2 and the pulse oximeter 3, and data such as thresholds which function as a comparison reference for determining the conditions of the heart, the lungs, and blood vessels.
The displaying section 8 includes a display screen. The displaying section 8 plots and displays biological information including the ETCO2 and SpO2 which are measured by the capnometer 2 and the pulse oximeter 3, on two-dimensional coordinates displayed on the display screen. The displaying section 8 displays the determination result (the condition (decease) of the respiratory system and the severity) of the condition determining section 6. The displaying section 8 may display the comparison reference for determining the conditions of the heart, the lungs, and blood vessels.
Next, a method of classifying decreases which cause heart failure will be described.
Depending on the ventilation and the blood flow, for example, the condition of the respiratory system can be classified into Patterns A to D such as shown in
Pattern A shown in
In
Moreover, PPAO2 indicates the partial pressure of oxygen in pulmonary arterial blood which is the partial pressure of oxygen contained in the blood from the vena cava. “PPAO2: 40 mmHg” means that the partial pressure of oxygen in pulmonary arterial blood is 40 mmHg. PPACO2 indicates the partial pressure of carbon dioxide in pulmonary arterial blood which is the partial pressure of carbon dioxide contained in the blood from the vena cava. “PPACO2: 46 mmHg” means that the partial pressure of carbon dioxide in pulmonary arterial blood is 46 mmHg.
Oxygen (PlO2: 150 mmHg) sucked from the nose and mouth of the subject is introduced into the lungs through the airway 11 as indicated by the arrow 12. Carbon dioxide (ETCO2: 40 mmHg) which has undergone gas exchange in the lungs is discharged from the nose and the mouth through the airway 11 to the outside of the body as indicated by the arrow 13.
Gas exchange in which oxygen is introduced and carbon dioxide is discharged is performed between alveoli 14a, 14b and pulmonary capillaries 15a, 15b which surround the alveoli.
Part of PlO2: 150 mmHg is lost until oxygen reaches the alveoli 14a, 14b, and the partial pressure is lowered. As a result, the alveolar oxygen partial pressure which is the partial pressure of oxygen in the alveoli is 100 mmHg.
The blood (PPAO2: 40 mmHg, PPACO2: 46 mmHg) from the vena cava (not shown) is sent to the pulmonary capillaries 15a, 15b via the heart (not shown) through the pulmonary arteries 16a, 16b.
In gas exchange, the blood in the pulmonary capillaries 15a, 15b introduces oxygen from the air in the alveoli 14a, 14b, and pushes out carbon dioxide in the blood into the alveoli 14a, 14b. When oxygen is introduced from the alveoli 14a, 14b, the partial pressure of oxygen in the blood is raised from 40 mmHg to 95 mmHg. When carbon dioxide is pushed out from the blood, the partial pressure of carbon dioxide in the blood is lowered from 46 mmHg to 40 mmHg. The blood which has undergone gas exchange in the alveoli 14a, 14b in the pulmonary capillaries 15a, 15b is sent to the pulmonary veins 17a, 17b. The blood in the pulmonary veins 17a, 17b flows as indicated by the arrow 18 to be sent to the aorta (not shown) via the heart.
In
Furthermore, “SpO2: 98%” means that the arterial blood oxygen saturation is 98%. This value is obtained from the oxygen dissociation curve shown in
As shown in
Pattern B shown in
Since the alveoli 14a are collapsed, the oxygen does not reach the alveoli 14a. Therefore, gas exchange is performed only between the normal alveoli 14b and the pulmonary capillaries 15b, and is not performed between the collapsed alveoli 14a and the pulmonary capillaries 15a. Therefore, the blood flown from the pulmonary artery 16a does not undergo gas exchange in the lung, and flows out as it is from the pulmonary vein 17a, and the oxygen partial pressure of 40 mmHg and carbon dioxide partial pressure of 50 mmHg in the blood remain as they are.
The blood (oxygen partial pressure: 40 mmHg, carbon dioxide partial pressure: 50 mmHg) in the pulmonary vein 17a is mixed with the blood (oxygen partial pressure: 95 mmHg, carbon dioxide partial pressure: 43 mmHg) in the pulmonary vein 17b, and then flows as indicated by the arrow 18 to be sent to the aorta via the heart. In the arterial blood, as result, the PaO2 is 70 mmHg, and the PaCO2 is 45 mmHg. The value of the SpO2 with respect to PaO2: 70 mmHg is SpO2: 90% from the oxygen dissociation curve of
The carbon dioxide which is discharged to the outside of the body through the airway 11 consists of only the carbon dioxide that has undergone gas exchange in the normal alveoli 14b, and carbon dioxide is not discharged from the collapsed alveoli 14a. As a result, the ETCO2 discharged to the outside of the body is 43 mmHg. In the case of Pattern B, as described above, the value (45 mmHg) of the PaCO2 is measured as a value which is slightly higher than the value (43 mmHg) of the ETCO2.
Pattern C shown in
The pressure of the pulmonary capillaries 15a is raised, water in blood leaks into the alveoli 14a, and water 21 stays in the alveoli 14a. Therefore, impaired diffusion occurs between the alveoli 14a and the pulmonary capillaries 15a, and the efficiency of gas exchange between the alveoli 14a and the pulmonary capillaries 15a is lowered. Gas exchange between the alveoli 14b and the pulmonary capillaries 15b is normally performed.
Due to the water 21 in the alveoli 14a, the blood in the pulmonary capillaries 15a hardly introduces oxygen from the alveoli 14a. Therefore, the oxygen partial pressure (20 mmHg) of the blood in the pulmonary artery 16a is raised only to 70 mmHg in the pulmonary vein 17a. Due to the water 21 in the alveoli 14a, moreover, the blood in the pulmonary capillaries 15a hardly pushes out carbon dioxide into the alveoli 14a. Therefore, the carbon dioxide partial pressure (56 mmHg) of the blood in the pulmonary artery 16a is lowered only to 54 mmHg also in the pulmonary vein 17a. The value of the PPAO2 is lowered to 20 mmHg by the reduction of the arterial blood oxygen partial pressure (PaO2).
The blood (oxygen partial pressure: 70 mmHg, carbon dioxide partial pressure: 54 mmHg) in the pulmonary vein 17a is mixed with the blood (oxygen partial pressure: 90 mmHg, carbon dioxide partial pressure: 50 mmHg) in the pulmonary vein 17b, and then flows as indicated by the arrow 18 to be sent to the aorta via the heart. In the arterial blood, as result, the PaO2 is 60 mmHg, and the PaCO2 is 52 mmHg. The value of the SpO2 with respect to PaO2: 60 mmHg is SpO2: 85% from the oxygen dissociation curve of
The carbon dioxide which is discharged to the outside of the body through the airway 11 consists of the carbon dioxide that has undergone gas exchange in the alveoli 14a in which impaired diffusion occurs, and the carbon dioxide that has undergone gas exchange in the normal alveoli 14b. Therefore, 20 mmHg which is the carbon dioxide partial pressure in the alveoli 14a, and 50 mmHg which is the carbon dioxide partial pressure in the alveoli 14b are mixed with each other, and the ETCO2 which is discharged to the outside of the body is 30 mmHg. In the case of Pattern C, in this way, the value (30 mmHg) of the ETCO2 is measured as a value which is lower than the value (52 mmHg) of the PaCO2.
Pattern D shown in
The blood in the pulmonary artery 16a does not flow into the pulmonary capillaries 15a and the pulmonary vein 17a because of the constriction in peripheral blood vessels. Therefore, gas exchange between the alveoli 14a and the pulmonary capillaries 15a is not performed. Since gas exchange is not performed, the carbon dioxide partial pressure in the alveoli 14a is equal to that in the inspired gas or 0 mmHg.
By contrast, normal gas exchange is performed between the alveoli 14b and the pulmonary capillaries 15b. Therefore, the oxygen partial pressure which is 30 mmHg in the blood in the pulmonary artery 16b is raised to 90 mmHg in the blood in the pulmonary vein 17b, and the carbon dioxide partial pressure which is 46 mmHg in the blood in the pulmonary artery 16b is lowered to 40 mmHg in the blood in the pulmonary vein 17b. As a result of gas exchange, the carbon dioxide partial pressure in the alveoli 14b is 40 mmHg. The value of the PPAO2 is lowered to 30 mmHg by an influence of the reduction of the carbon dioxide partial pressure.
Since the blood flow does not exist in the pulmonary vein 17a, the blood (oxygen partial pressure: 90 mmHg, carbon dioxide partial pressure: 40 mmHg) in the pulmonary vein 17b flows as indicated by the arrow 18 to be sent to the aorta via the heart. In the arterial blood, as result, the PaO2 is 90 mmHg, and the PaCO2 is 40 mmHg. The value of the SpO2 with respect to PaO2: 90 mmHg is SpO2: 97% from the oxygen dissociation curve of
The carbon dioxide which is discharged to the outside of the body through the airway 11 consists of the carbon dioxide in the alveoli 14a where gas exchange is not performed, and that in the alveoli 14b where normal gas exchange is performed. Therefore, 50 mmHg which is the carbon dioxide partial pressure in the alveoli 14a, and 40 mmHg which is the carbon dioxide partial pressure in the alveoli 14b are mixed with each other, and the ETCO2 which is discharged to the outside of the body is 20 mmHg. In the case of Pattern D, in this way, the value (20 mmHg) of the ETCO2 is measured as a value which is largely lower than the value (40 mmHg) of the PaCO2.
In
Since the respiratory system is in the normal condition, the subjects do not fall under any of pulmonary congestion (pulmonary hypertension), pulmonary edema, and dead alveoli (NA: Not Applicable). In the arterial blood, the value of the PaO2 was about 95 mmHg, and that of the PaCO2 was about 40 mmHg. The value (98% in the example of
In
Because of the poor ventilation caused by collapse of alveoli, the subjects do not fall under pulmonary congestion (pulmonary hypertension) and pulmonary edema, and fall under dead alveoli (symbol of ◯). In the arterial blood, the value (70 mmHg in the example of
In
It is supposed that, because of the poor ventilation caused by pulmonary edema, the blood volume in blood vessels was increased, the pressure in pulmonary capillaries was raised, and water in blood oozed out into alveoli. Therefore, the subjects can fall under any of pulmonary congestion (pulmonary hypertension), pulmonary edema, and dead alveoli (symbol of ◯). Pulmonary edema has characteristics that the severities of pulmonary congestion and pulmonary hypertension are acutely impaired. In the arterial blood, the value (60 mmHg in the example of
In
Because of poor blood flow caused by constriction of pulmonary blood vessels, the subjects fall under pulmonary congestion (pulmonary hypertension), but do not fall under pulmonary edema and dead alveoli. Poor blood flow caused by constriction of pulmonary blood vessels has characteristics that chronic pulmonary congestion and pulmonary hypertension become severe. In the arterial blood, the value of the PaO2 was about 90 mmHg, the value of the PaCO2 was about 40 mmHg, oxygen was slightly low, and carbon dioxide was normal. The value (97% in the example of
For example, the case where the measured value of the ETCO2 is larger than 36 mmHg, and the value of the SpO2 is larger than 96% is classified into the condition 41 of “Condition of respiratory system is normal.”
For example, the case where the measured value of the ETCO2 is larger than 40 mmHg, and the value of the SpO2 is smaller than 95% is classified into the condition 42 of “Respiratory system is in condition where ventilation is poor.”
For example, the case where the measured value of the ETCO2 is smaller than 36 mmHg, and the value of the SpO2 is smaller than 90% is classified into the condition 43 of “Respiratory system is in condition of pulmonary edema.”
For example, the case where the measured value of the ETCO2 is smaller than 28 mmHg, and the value of the SpO2 is larger than 94% is classified into the condition 44 of “Respiratory system is in condition of pulmonary congestion or pulmonary hypertension which is chronic and highly severe.”
The condition of one of the heart, the lungs, and blood vessels which is classified based on the ETCO2 and the oxygen transport parameter or the metabolic parameter (for example, the SpO2, blood gas information, the blood pressure, the cardiac output, the cardiac index, the pulsation rate, the body temperature, the pulse rate, and the heart rate) may be displayed in the form of a graph on the displaying section 8. The blood gas information may be measurement items of a blood gas test of the arterial blood oxygen partial pressure (PaO2), the arterial blood carbon dioxide partial pressure (PaCO2), the pH, the Hb, the Hct, and the like.
Next, the operation of the monitoring apparatus 1 will be described.
The value of the ETCO2 which is measured by using the capnometer 2, and that of the SpO2 which is measured by using the pulse oximeter 3 are input to the processing device 5. The condition determining section 6 of the processing device 5 compares the input values of the ETCO2 and the SpO2 with the thresholds which are previously set. The thresholds which function as a comparison reference are previously stored in the memory section 7.
Here, the thresholds which function as a comparison reference mean the values of the ETCO2 and the SpO2 which function to as a comparison reference for classifying conditions of the respiratory system that have been described with reference to
In a manner similar to that of the classification which has been described with reference to
On the two-dimensional coordinates displayed on the display screen of the displaying section 8, the section plots biological information A including the measurement data of the ETCO2 measured by the capnometer 2 and those of the SpO2 measured by the pulse oximeter 3. The displaying section 8 further displays the determination result (the condition (decease) of the respiratory system and the severity) of the condition determining section 6. The displaying section 8 may display the comparison reference on the two-dimensional coordinates to displayed on the display screen of the section, as regions defined by the thresholds of the SpO2 and the ETCO2 as shown in
According to the above-described monitoring apparatus 1 of the embodiment, the values of the ETCO2 and the SpO2 are measured from the subject, whereby the condition of the respiratory system which causes heart failure can be determined more finely. Therefore, for example, it is possible to determine the condition where both the ventilation and the blood flow are satisfactorily performed, that where the ventilation is poor because of collapse of the alveoli 14a, that where the ventilation is poor because of pulmonary edema due to acute severity of pulmonary congestion or pulmonary hypertension, and that where the blood flow is poor because of chronic severity of pulmonary congestion or pulmonary hypertension. According to the embodiment, therefore, it is possible to determine one of the conditions of the heart, the lungs, and blood vessels which cause onset of heart failure.
Moreover, the displaying section 8 plots and displays the measurement data of the ETCO2 and those of the SpO2 on the two-dimensional coordinates, and therefore the medical person can visually evaluate the conditions of the heart, the lungs, and blood vessels. Furthermore, the medical person can know rapidly and easily a change of the condition of heart failure by observing the locus of the plots (the locus of time series data of the biological information A) and regions (comparison reference) corresponding to the conditions 41 to 44 which are displayed on the displaying section 8.
When the medical person evaluates in combination the measurement data of the ETCO2 and those of the SpO2, the conditions of the heart, the lungs, and blood vessels can be quantitatively evaluated. Therefore, also when these values of an unconscious subject are measured, for example, the degree of progress of the disease can be determined, and hence an adequate procedure can be rapidly applied to the subject.
The ETCO2 can be measured by using the capnometer 2, and the SpO2 can be measured by using the pulse oximeter. Therefore, the ETCO2 and the SpO2 can be simply measured by using non-invasive devices, and the monitoring apparatus 1 can be easily used in home medicine.
Next, a data change which is due to the posture of the subject, and which is measured by the monitoring apparatus 1 will be described with reference to
The subject changed the posture from a supine posture in which the subject lay on the back on a bed, to a sitting posture in which the subject on the bed raised only the upper body, and data of the ETCO2 and the SpO2 were measured from the subject.
The values of the ETCO2 and the SpO2 were measured by using the capnometer 2 and the pulse oximeter 3. The plurality of plot points (▪: supine posture, Δ: sitting posture) indicated in
Moreover, the subjects were asked about a change of the degree of pain which was felt when the posture was changed from a supine posture to a sitting posture. As a result, it was noted that, as shown in
As described above, when the ETCO2 and the SpO2 are measured and evaluated in combination, it is possible to quantitatively determine the existence or non-existence and severity of pulmonary edema. Also when these values are measured from an unconscious subject, for example, the existence or non-existence and degree of progress of pulmonary edema can be determined, and hence an adequate procedure can be rapidly applied to the subject. Moreover, this method can detect onset of pulmonary edema caused by an excess of transfusion, and can be applied also to non-invasive monitoring of transfusion management.
Next, a modification (monitoring apparatus 50) of the monitoring apparatus 1 will be described with reference to
The severities of pulmonary congestion and pulmonary hypertension are diagnosed by the monitoring apparatus 50 in the following manner.
The SpO2 and the pulse wave are measured by using the pulse oximeter 3, and the electrocardiogram waveform is measured by using the electrocardiogram monitor 4. The cardiac output is calculated based on the electrocardiogram waveform and the pulse wave propagation time of the pulse wave. For example, the method of calculating the cardiac output is similar to that disclosed in JP-A-2005-312947 which has been filed by the assignee of the present application.
The values of the ETCO2 and the cardiac output are measured from a plurality of subjects suffering from pulmonary congestion or pulmonary hypertension. The measurement from each subject is continuously performed during a period from a time when symptoms get worse, to that when the disease is cured. The measured values are stored as comparison reference data in the memory section 7.
The plurality of plot points (each is indicated by a symbol of ◯) shown in
The measured data are input to the processing device 5, and formed as a graph similarly with
The invention is not limited to the above-described embodiment and modification, and may be adequately subjected to modifications, improvements, and the like. In addition, the materials, shapes, dimensions, values, forms, numbers, places, and the like of the components of the above-described embodiment are arbitrary and not limited insofar as the invention is achieved.
According to the monitoring apparatus of the presently disclosed subject matter, it is possible to determine one of the conditions of the heart, the lungs, and blood vessels which cause onset of heart failure.
Number | Date | Country | Kind |
---|---|---|---|
2014-011350 | Jan 2014 | JP | national |
Number | Name | Date | Kind |
---|---|---|---|
4368740 | Binder | Jan 1983 | A |
6428483 | Carlebach | Aug 2002 | B1 |
8414488 | Colman | Apr 2013 | B2 |
20020082511 | Carlebach et al. | Jun 2002 | A1 |
20050098527 | Yates, III | May 2005 | A1 |
20050203352 | Al-Ali et al. | Sep 2005 | A1 |
20060102581 | Yates, III | May 2006 | A1 |
20060108363 | Yates, III | May 2006 | A1 |
20080000866 | Yates, III | Jan 2008 | A1 |
20080188733 | Al-Ali | Aug 2008 | A1 |
20080300471 | Al-Ali et al. | Dec 2008 | A1 |
20100069725 | Al-Ali | Mar 2010 | A1 |
20100317933 | Colman et al. | Dec 2010 | A1 |
20100317986 | Colman et al. | Dec 2010 | A1 |
20110040713 | Colman et al. | Feb 2011 | A1 |
20110098592 | Colman et al. | Apr 2011 | A1 |
20120022388 | Pittman et al. | Jan 2012 | A1 |
20120145152 | Lain et al. | Jun 2012 | A1 |
20130204099 | Colman et al. | Aug 2013 | A1 |
20130274617 | Hosaka et al. | Oct 2013 | A1 |
20130289364 | Colman et al. | Oct 2013 | A1 |
20140012096 | Nomura | Jan 2014 | A1 |
20140155775 | Colman et al. | Jun 2014 | A1 |
20140155776 | Colman et al. | Jun 2014 | A1 |
20140330092 | Al-Ali et al. | Nov 2014 | A1 |
20160174907 | Colman et al. | Jun 2016 | A1 |
20160345843 | Colman et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
2003-532442 | Nov 2003 | JP |
2007-527776 | Oct 2007 | JP |
2011-505177 | Feb 2011 | JP |
2012-523262 | Oct 2012 | JP |
2013-220175 | Oct 2013 | JP |
Entry |
---|
Search Report dated May 27, 2015, issued by the European Patent Office in counterpart European Application No. 15152275.2. |
Communication issued by the Japanese Patent Office dated Aug. 22, 2017, in counterpart Japanese Patent Application No. 2014-011350. |
Communication dated Apr. 3, 2018, by the Japanese Patent Office in copending Application No. 2014-011350. |
Number | Date | Country | |
---|---|---|---|
20150208927 A1 | Jul 2015 | US |